Navigation Links
febit Forms Scientific Advisory Board

Five renowned researchers to guide febit's research and business

development activities

MEDFORD, Mass. and HEIDELBERG, Germany, March 31 /PRNewswire/ -- febit group, the provider of the unique microfluidic microarray system Geniom, today announced the formation of a Scientific Advisory Board (SAB) consisting of leading authorities at the forefront of genetics and genomics research. The SAB members, from top research institutions and companies, will provide expert advice on febit's research and development activities associated with its portfolio development.
The interdisciplinary febit Scientific Advisory Board consists of:

-- Mark Chee, Ph.D., who will serve as chairman. As a former scientist of

Affymetrix and co-founder of Illumina (ILMN) he has an exceptional

knowledge of microarray technologies and market.

-- Karoly Nikolich, Ph.D., who will serve as vice chairman. Dr. Nikolich

was formerly the executive director of the Neuroscience Institute of

Stanford. He is an entrepreneur and consultant, and has over 20 years

of biotechnology industry experience in R&D.

-- David Lockhart, Ph.D., the CSO of Amicus Therapeutics. Dr. Lockhart

brings many years of industry experience and achievements, including

credit as the primary inventor and developer of genome-wide

gene-expression profiling with high-density DNA arrays when he was at


-- Mostafa Ronaghi, Ph.D., one of the inventors of Pyrosequencing,

molecular inversion probe assay and Nextbio search engine. He has

co-founded four companies and serves on the board of director and

scientific advisory board of several companies.

-- Jeffrey Trent, Ph.D., the president and scientific director of the

Translational Genomics Research Institute (TGen) in Phoenix, Ariz. In

addition to his expertise in cDNA-microarray, Dr. Trent was one of the

leading scientists with the "Human Genome Project."

"The formation of febit's scientific advisory board brings together key thought leaders with deep insight into the needs of the scientific community in genomic research," said Cord F. Staehler, CEO of febit holding gmbh. "We look forward to their support and guidance that will help us realize the full potential of febit's portfolio of unique applications for existing and future strategic partnerships."

Dr. Chee added, "It is our goal to help febit meet scientists' needs and open up new possibilities in genomic research. febit's Geniom technology is a unique tool for various applications in this field from microarray analysis to synthetic biology."

About febit

febit enables scientists to read, write and understand the code of life: DNA. With its unique Geniom technology and services, febit is the only company that puts the control of simplified genomic research in the hand of the user. The seamless integration of DNA synthesis and analysis and the superior support in experiment design and bioinformatics helps to understand data and turn it into results. febit's team of experienced scientists is dedicated to support customers to solve the challenge of understanding biological processes. Geniom is a technological and service platform successfully implemented in basic and applied research by renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes, providing superior time- and cost-efficiency combined with an unsurpassed spectrum of applications.


febit holding gmbh Russo Partners, LLC

Eva Sterzel David Schull or Wendy Lau

Public Relations Manager +1-212-845-4271

+49 (6221) 6510-300

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales
2. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
3. Technology Transforms Market Research in Pharmaceutical Industry
4. Anthera Pharmaceuticals Forms Scientific Advisory Board
5. Transgenomic, Inc. Forms Scientific Advisory Board
6. ADM Forms Industrial Chemicals Group
7. iGuard Transforms Drug Safety Alert and Update Process
8. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
9. NASA technology forms the basis for a new nanotechnology company
10. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
11. Boston Scientific Announces Schedule for ACC 2008
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
Breaking Biology Technology:
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):